Mateon Therapeutics Inc. (MATN)
| Market Cap | 30.02M |
| Revenue (ttm) | 1.74M |
| Net Income (ttm) | -9.54M |
| Shares Out | 89.60M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $0.3350 |
| Previous Close | $0.3300 |
| Change ($) | 0.0050 |
| Change (%) | 1.52% |
| Day's Open | 0.3260 |
| Day's Range | 0.3200 - 0.3500 |
| Day's Volume | 403,319 |
| 52-Week Range | 0.08 - 0.35 |
News
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported po...
AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel P...
About MATN
Mateon Therapeutics, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment... [Read more...]
| Industry Biotechnology | IPO Date Aug 26, 1993 |
| CEO Dr. Vuong Trieu | Employees 13 |
| Stock Exchange OTCMKTS | Ticker Symbol MATN |